Prediction of response to pegylated-interferon- and ribavirin therapy in chinese patients infected with different hepatitis C virus genotype

Virology Journal

Volumn 9, Issue , 2012, Pages

  Guo, Xiaoyan ^a   Zhao, Zhixin ^a   Xie, Junqiang ^a   Cai, Qingxian ^a   Zhang, Xiaohong ^a   Peng, Liang ^a   Gao, Zhiliang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatitis C; IL 28B; Relapse; Sustained virological response; Treatment

Indexed keywords

GLYCINE; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; TYROSINE;

ADULT; ALLELE; ARTICLE; CHINESE; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; NULL VIROLOGICAL RESPONSE; RELAPSE; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84862280654     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-123     Document Type: Article

References (29)

1. Global epidemiology and burden of hepatitis C. Ray KW, Microbes Infect 2002 4 1219 1225 10.1016/S1286-4579(02)01649-0 12467763
2. Hepatitis C treatment: current and future perspectives. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, et al. Virol J 2010 7 296 10.1186/1743-422X-7-296 21040548
3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102-5 11583749
4. Current status and future directions in the management of chronic hepatitis C. Aman W, Mousa S, Shiha G, Mousa SA, Virol J 2012 9 57 10.1186/1743-422X-9-57 22385500
5. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, Haussinger D, Diago M, Carosi G, Dhumeaux D, et al. N Engl J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
6. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, et al. J Hepatol 2012 56 34 40 10.1016/j.jhep.2011.03.029 21703176
7. Treatment of chronic hepatitis C in Asia: when East meets West. Yu ML, Chuang WL, J Gastroenterol Hepatol 2009 24 336 345 10.1111/j.1440-1746.2009. 05789.x 19335784
8. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, Rsquo CO, O'Huigin C, Kidd J, Kidd K, Khakoo SI, et al. Nature 2009 461 7265 798 801 10.1038/nature08463 19759533
9. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al. Nat Genet 2009 41 1100 1104 10.1038/ng.447 19749758
10. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al. Nature 2009 461 399 401 10.1038/nature08309 19684573
11. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al. Nat Genet 2009 41 1105 1109 10.1038/ng.449 19749757
12. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP, Nat Immunol 2003 4 69 77 12483210
13. IL-28, IL-29 and their class II cytokine receptor IL-28R. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al. Nat Immunol 2003 4 63 68 10.1038/ni873 12469119
14. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M, Hepatol Res 2010 40 449 460 10.1111/j.1872-034X.2010. 00671.x 20546329
15. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Ahlenstiel G, Booth DR, George J, J Gastroenterol 2010 45 903 910 10.1007/s00535-010-0287-4 20635099
16. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study. Imazeki F, Yokosuka O, Omata M, Expert Rev Anti Infect Ther 2010 8 497 499 10.1586/eri.10.30 20455677
17. Side effects of therapy of hepatitis C and their management. Fried MW, Hepatology 2002 36 237 S244 12407599
18. Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML, Hepatology 2011 53 367 368 10.1002/hep.24049 21254186
19. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al. Gastroenterology 2010 138 1338 1345 10.1053/j.gastro.2009. 12.056 20060832
20. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, et al. J Viral Hepat 2011 18 550 e560 10.1111/j.1365-2893.2011.01468.x 21914076
21. Effects of host and virus related factors on interferon-alpha+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients. Akram M, Idrees M, Zafar S, Hussain A, Butt S, Afzal S, Rehman IU, Liaqat A, Saleem S, Ali M, Butt A, Virol J 2011 8 234 10.1186/1743-422X-8-234 21575275
22. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Gao B, Hong F, Radaeva S, Hepatology 2004 39 880 890 10.1002/hep.20139 15057887
23. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E, Hepatology 2008 48 1753 1760 10.1002/hep.22543 18925643
24. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF, Trends Mol Med 2010 16 277 286 10.1016/j.molmed.2010.04.003 20537953
25. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG, Gastroenterology 2010 138 2307 2314 10.1053/j.gastro.2010.02.009 20176026
26. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, et al. Gut 2011 60 261 267 10.1136/gut.2010.223495 21068134
27. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y, J Hepatol 2010 52 672 680 10.1016/j.jhep.2009.10.034 20346532
28. Diagnosis, management, and treatment of hepatitis C: an update. Ghany MG, Strader DB, Thomas DL, Seeff LB, Hepatology 2009 49 1335 1374 10.1002/hep.22759 19330875
29. Classification of chronic hepatitis: diagnosis, grading and staging. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ, Hepatology 1994 19 1513 1520 10.1002/hep.1840190629 8188183